| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Leucylarginylproline is an inhibitor of angiotensin-converting enzyme (ACE). (IC₅₀ = 0.27 µM) [1]
|
|---|---|
| ln Vitro |
Blood pressure dropped after receiving 30 mg/kg of leucylproline intravenously. Two minutes after injection is when the mean blood pressure drops the most, by about 15 mmHg [1]. In the fourth hour following oral administration, leucylproline peptide lowers blood pressure by around 15 mmHg, and in the eighth hour, it has a maximal lowering effect of about 35 mmHg [2].
Leucylarginylproline, isolated from an α-zein thermolysin hydrolysate, demonstrates potent in vitro inhibitory activity against angiotensin-converting enzyme (ACE). The synthetic tripeptide L-Leu-L-Arg-L-Pro exhibited an IC₅₀ value of 0.29 µM in the ACE inhibition assay, confirming the activity of the isolated compound (H2, IC₅₀ = 0.27 µM). It was identified as the strongest ACE inhibitor among the peptides derived from the α-zein hydrolysate in this study. [1] |
| ln Vivo |
Intravenous administration of synthetic Leucylarginylproline (30 mg/kg) to anesthetized spontaneously hypertensive rats (SHR) induced a transient hypotensive effect.
The mean blood pressure decreased by approximately 15 mmHg, with the maximum reduction observed about 2 minutes post-injection. The blood pressure returned to its initial level approximately 5 minutes after administration. [1] |
| Enzyme Assay |
ACE inhibitory activity was assayed using a modified method based on Cushman and Cheung. The substrate hippuryl-L-histidyl-L-leucine (Hip-His-Leu) at 5 mM and the test inhibitor were dissolved in a 100 mM sodium borate buffer (pH 8.3) containing 300 mM NaCl.
The reaction mixture was incubated with 8 milliunits of rabbit lung ACE at 37°C for 30 minutes. The concentration of inhibitor required to inhibit 50% of the ACE activity under these conditions was defined as the IC₅₀ value. For the tested peptides, including Leucylarginylproline, their IC₅₀ values were determined using this assay system. [1] |
| Animal Protocol |
The in vivo hypotensive activity was evaluated in 11-week-old male spontaneously hypertensive rats (SHR). The rats were anesthetized via intraperitoneal injection of urethane at a dose of 2 g/kg.
A polyethylene cannula was inserted into the femoral vein for compound administration. Leucylarginylproline was dissolved in saline containing heparin. Carotid artery blood pressure was monitored continuously using a pressure transducer. A baseline injection of saline was first administered, followed by a single intravenous bolus injection of Leucylarginylproline at a dose of 30 mg/kg. Blood pressure changes were recorded. [1] |
| References |
|
| Additional Infomation |
Leucylarginylproline (Leu-Arg-Pro) is a tripeptide that was isolated from the enzymatic hydrolysis product of α-zein, a corn protein, using a thermophilic protease. Its amino acid sequence was identified by Edman degradation and confirmed by fast atom bombardment mass spectrometry (FAB-MS). The peptide contains a proline residue at its C-terminus, which is a common feature of many potent ACE inhibitors. Studies have shown that such peptides may exist naturally in food proteins and hold promise for the development of functional foods designed to control blood pressure. [1]
|
| Molecular Formula |
C17H32N6O4
|
|---|---|
| Molecular Weight |
384.47378
|
| Exact Mass |
384.249
|
| CAS # |
133943-59-6
|
| PubChem CID |
9929972
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
1.403
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
27
|
| Complexity |
562
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
O=C(O)[C@H]1N(C([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)N)=O)=O)CCC1
|
| InChi Key |
IBMVEYRWAWIOTN-AVGNSLFASA-N
|
| InChi Code |
InChI=1S/C17H32N6O4/c1-10(2)9-11(18)14(24)22-12(5-3-7-21-17(19)20)15(25)23-8-4-6-13(23)16(26)27/h10-13H,3-9,18H2,1-2H3,(H,22,24)(H,26,27)(H4,19,20,21)/t11-,12-,13-/m0/s1
|
| Chemical Name |
(2S)-1-[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6010 mL | 13.0049 mL | 26.0098 mL | |
| 5 mM | 0.5202 mL | 2.6010 mL | 5.2020 mL | |
| 10 mM | 0.2601 mL | 1.3005 mL | 2.6010 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
